

# Effects of 24R,25-Dihydroxyvitamin D3 on gamma-glutamyl transpeptidase and alkaline phosphatase activities in Rat Brains.

F. Darcy, L. Sindji, J.C. Peter, E. Garcion, A. Girault, Mustayeen A. Khan,

P. Brachet, X.T. Do.

### ▶ To cite this version:

F. Darcy, L. Sindji, J.C. Peter, E. Garcion, A. Girault, et al.. Effects of 24R,25-Dihydroxyvitamin D3 on gamma-glutamyl transpeptidase and alkaline phosphatase activities in Rat Brains.. Vitamin D, A Pluripotent Steroid Hormone-9th Workshop on Vitamin D, May 1994, Orlando, Florida, United States. hal-03193532

## HAL Id: hal-03193532 https://univ-angers.hal.science/hal-03193532

Submitted on 8 Apr 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## EFFECTS OF 24R,25-DIHYDROXYVITAMIN D3 ON γ-GLUTAMYL-TRANSPEPTIDASE AND ALKALINE PHOSPHATASE ACTIVITIES IN RAT BRAINS

F.DARCY\*, L.SINDJI\*, J.C.PETER\*\*, E.GARCION\*, A.GIRAULT\*\*, M.A.KHAN\*\*\*, P.BRACHET\* and X.T.DO\*\*, Unité INSERM 298\* and Laboratoire de Biochimie-Médecine/Pharmacie\*\*, CHU, Chimie de Coordination-Pharmacie\*\*\*, F-49100 Angers, France.

Introduction.  $\gamma$ -Glutamyl transpeptidase (GGT) and alkaline phosphatase (AP) are two marker enzymes of the blood-brain barrier (BBB) which plays a major role in the control of brain homeostasis. Do *et al.* (1) have recently demonstrated that intraperitoneal (IP) injections of 24R,25-dihydroxyvitamin D3 (24,25-(OH)2 D3) induce an increase in GGT and AP activities in rat kidneys. It was then of interest to investigate whether these enzymatic activities could also be modified in ratbrains by vitamin D3 metabolites. In addition to the effects of 24,25-(OH)2 D3, already demonstrated in the kidney, we are also studying those of 1,25-(OH)2 D3, considered as the biologically active metabolite. Since rat enzymatic activities are more elevated during night than during day (2), the experiments were carried out throughout the night period.

Materials and Methods. Female Sprague-Dawley rats  $(250 \pm 30 \text{ g})$  were conditioned for 3 weeks before experiments at  $20 \pm 2$  °C in artificial lighting from 8.00 a.m. to 8.00 p.m. and in darkness during the remaining period. Six animals per series received at various times during the night a single IP injection of 24,25-(OH)<sub>2</sub> D<sub>3</sub>, 1,25-(OH)<sub>2</sub> D<sub>3</sub> or vehicle alone (control rats). Brains were removed from 6.00 a.m. to 8.00 a.m., when enzyme activities are maximum, then homogeneized in a potter device. After centrifugation at 2000 g for 20 min., the activities of GGT (GGT kit, Boehringer) and of AP (Enzyline kit, Biomérieux) were tested in the supernatants together with the protein concentration (Bio-Rad Laboratories).

<u>Results and Discussion.</u> In preliminary experiments, rat brains were collected 6 h after the IP injection of various doses of 24,25-(OH)<sub>2</sub> D<sub>3</sub> (from 5 to 100 ng/g.b.w.). Whereas the lower doses stimulated GGT and AP activities, the highest doses displayed inhibitory properties. Further experiments were carried out with the physiological dose of 10 ng/g.b.w.

Kinetic studies showed that  $24,25-(OH)_2 D_3$  induces in brain a constant increase in GGT activity from 2 h to 5 h, with a maximum of 67 % at 5 h (Fig. 1A), and a diphasic increase in AP activity (Fig. 1B). In contrast to that observed in the kidney (3),  $24,25-(OH)_2 D_3$  stimulates in the brain more intensely GGT than AP activity.

Interestingly, the IP injection of 10 ng/g.b.w. of 1,25-(OH)<sub>2</sub> D<sub>3</sub> induced first a sharp increase (up to 140 % at 3 h) followed by a decrease (-67 % and -77 % at 8 h and 24 h) in GGT cerebral activity. Although these data need to be confirmed by additional experiments, they suggest a down-regulation of GGT activity induced by 1,25-(OH)<sub>2</sub> D<sub>3</sub>. In contrast, AP activity was constantly enhanced from 3 h to 6 h, reaching its maximum level (50%) at 4 h, and then returned to its basal level.




Figure 1: Kinetic effects of 24,25-(OH)<sub>2</sub> D<sub>3</sub> on GGT (A) and AP (B) activities in rat brains (Student's t-test: \* p < 0.05, \*\* p < 0.01).

These results clearly demonstrate that both 24,25-(OH)<sub>2</sub> D<sub>3</sub> and 1,25-(OH)<sub>2</sub> D<sub>3</sub> are active on cerebral GGT and AP activities. This is of particular interest in the case of GGT, likely involved in the aminoacid transport through the BBB (4). In addition, the action of 1,25-(OH)<sub>2</sub> D<sub>3</sub> on the central nervous system (CNS) has been recently evidenced by in vitro (5) and in vivo (6) studies. Considering that both GGT and 1,25-(OH)<sub>2</sub> D<sub>3</sub> could be involved in the physiopathology of the CNS, their interrelationships should be further investigated.

<u>Acknowledgments.</u> We wish to thank Drs Schneider, Weber and Fischer (Hoffmann-Laroche, Basel, Switzerland) for their kind gift of vitamin D metabolites, and C. Fandard, R. Breget and P. Planchenault for excellent technical assistance.

#### References.

E

1-Do, T.X., Prelot, M., Planchenault, P. and Girault, A. (1991), In Vitamin D, gene regulation, structure-function analysis and clinical application, pp 310-311, W. de Gruyter, Berlin, New York.

2-Do, T.X., Boisnard, P., Girault, A., Planchenault, P., Breget, R. and Prelot, M. (1992), Sci.Tech.Anim.Lab., 17, 207-211.

3-Do, T.X., Peter, J.C., Girault, A., Rabjeau, A., Bouet, G., Sindji, L. and Darcy, F. (1994), 9th Workshop on Vitamin D, Orlando, Florida (abstract).

4-Cardelli-Cangiano, P., Fiori, A., Cangiano, C., Barberini, F., Allegra, P., Peresempio, V. and Strom, R. (1987), J.Neurochem., 49, 1667-1675.

5-Naveilhan, P., Neveu, I., Baudet, C., Ohyama, K.Y., Brachet, P. and Wion, D. (1993), Neuroreport, 5, 255-257.

6-Saporito, M.S., Wilcox, H.M., Hartpence, K.C., Lewis, M.E., Vaught, J.L. and Carswell., S. (1993), Exp.Neurol., 123, 295-302.